Amir Reichman - 01 Jan 2023 Form 3 Insider Report for BiondVax Pharmaceuticals Ltd. (BVXV)

Role
Chief Executive Officer, Director
Signature
/s/ Amir Reichman
Issuer symbol
BVXV
Transactions as of
01 Jan 2023
Net transactions value
$0
Form type
3
Filing time
03 Jan 2023, 14:05:50 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BVXV Restricted Share Units 01 Jan 2023 Ordinary Shares 24,000,000 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted share units were granted on March 2, 2021, and vest on an annual basis for a period of five years.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
F3 Each restricted share unit represents a contingent right to receive one ordinary share.